Ventyx Biosciences, Inc. (VTYX) 10-Year Financial Performance & Capital Metrics

VTYX • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutVentyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.Show more

Revenue $0
EBITDA -$147M +29.0%
Net Income -$135M +30.0%
EPS (Diluted) -1.97 +40.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -54.27% +15.9%
ROIC -50.33% +20.1%
Debt/Equity 0.04 -17.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 98 (top 2%)

✗Weaknesses

✗Shares diluted 17.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM30.1%

EPS CAGR

10Y-

5Y-

3Y-

TTM36.44%

ROCE

10Y Avg-52.33%

5Y Avg-52.33%

3Y Avg-53.67%

Latest-57.18%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-
Operating Expenses+	4.18M	7.05M	67.15M	113.14M	207.99M	148.45M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	628K	684K	8.67M	25.4M	32.23M	31.45M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	3.55M	6.37M	58.48M	87.74M	175.77M	117M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-4.18M	-7.05M	-67.15M	-113.14M	-207.99M	-148.45M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	-0.69%	-8.52%	-0.68%	-0.84%	0.29%
EBITDA+	0	0	-67.12M	-112.67M	-207.05M	-147.1M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	-	-	-0.68%	-0.84%	0.29%
D&A (Non-Cash Add-back)	4.18M	7.05M	30K	470K	941K	1.35M
EBIT	-4.18M	-7.05M	-83.65M	-113.14M	-207.99M	-148.45M
Net Interest Income+	-145.85K	-357.64K	-21K	4.67M	15.07M	13.42M
Interest Income	146	358	78K	4.67M	15.07M	13.42M
Interest Expense	146K	358K	99K	0	0	0
Other Income/Expense	-147K	-21.12M	-16.6M	4.71M	15.03M	13.33M
Pretax Income+	-4.33M	-28.17M	-83.75M	-108.43M	-192.96M	-135.12M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1.03%	1%	1%	1%	1%	1%
Net Income+	-4.47M	-28.17M	-83.75M	-108.43M	-192.96M	-135.12M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	-5.3%	-1.97%	-0.29%	-0.78%	0.3%
Net Income (Continuing)	-4.33M	-28.17M	-83.75M	-108.43M	-192.96M	-135.12M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-2.29	-0.56	-1.69	-2.06	-3.30	-1.97
EPS Growth %	-	0.76%	-2.02%	-0.22%	-0.6%	0.4%
EPS (Basic)	-2.29	-0.56	-1.69	-2.06	-3.30	-1.97
Diluted Shares Outstanding	1.96M	50.3M	50.41M	52.47M	58.54M	68.48M
Basic Shares Outstanding	1.96M	50.3M	50.41M	52.47M	58.54M	68.48M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	349K	245K	263.02M	330.69M	264.35M	229.63M
Cash & Short-Term Investments	309K	244K	258.58M	317.94M	252.22M	217.32M
Cash Only	309K	244K	70.79M	64.82M	51.58M	27.26M
Short-Term Investments	0	0	187.78M	253.12M	200.64M	190.06M
Accounts Receivable	0	0	0	0	0	1M
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	0	12.75M	12.13M	11.3M
Total Non-Current Assets+	0	0	28.46M	40.71M	13.35M	46.94M
Property, Plant & Equipment	0	0	254K	1.94M	12.27M	10.28M
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	28.15M	38.67M	0	35.62M
Other Non-Current Assets	0	0	60K	96K	1.08M	1.03M
Total Assets+	349K	245K	291.48M	371.4M	277.69M	276.56M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	-0.3%	1188.72%	0.27%	-0.25%	-0%
Total Current Liabilities+	631K	1.4M	12.28M	16.36M	22.27M	12.78M
Accounts Payable	362K	1.1M	4.66M	6.43M	5.76M	3.13M
Days Payables Outstanding	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	0	0
Current Ratio	0.55x	0.17x	21.41x	20.21x	11.87x	17.97x
Quick Ratio	0.55x	0.17x	21.41x	20.21x	11.87x	17.97x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	3.85M	29.5M	0	1.15M	11.51M	9.74M
Long-Term Debt	3.85M	12.65M	0	0	0	0
Capital Lease Obligations	0	0	0	1.15M	11.51M	9.74M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	16.85M	0	0	0	0
Total Liabilities	4.48M	30.9M	12.28M	17.5M	33.77M	22.52M
Total Debt+	3.85M	12.65M	0	1.56M	12.51M	10.79M
Net Debt	3.54M	12.4M	-70.79M	-63.26M	-39.07M	-16.47M
Debt / Equity	-	-	-	0.00x	0.05x	0.04x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-28.63x	-19.69x	-678.25x	-	-	-
Total Equity+	-4.13M	-30.65M	279.2M	353.89M	243.92M	254.04M
Equity Growth %	-	-6.43%	10.11%	0.27%	-0.31%	0.04%
Book Value per Share	-2.11	-0.61	5.54	6.74	4.17	3.71
Total Shareholders' Equity	-4.13M	-30.65M	279.2M	353.89M	243.92M	254.04M
Common Stock	0	0	5K	6K	6K	7K
Retained Earnings	-4.33M	-32.5M	-117.8M	-226.22M	-419.19M	-554.31M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	-58K	-1.12M	-50K	157K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.64M	-6.2M	-38.65M	-98.77M	-166.52M	-130.87M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-1.34%	-5.24%	-1.56%	-0.69%	0.21%
Net Income	-4.33M	-28.17M	-83.75M	-108.43M	-192.96M	-135.12M
Depreciation & Amortization	0	0	30K	470K	941K	1.35M
Stock-Based Compensation	0	45K	2.73M	16.57M	28.59M	22.93M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	1.09M	21.12M	38.32M	-2.23M	-8.89M	-9.47M
Working Capital Changes	591K	812K	4.02M	-5.16M	5.81M	-10.56M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	361K	591K	2.44M	1.61M	-745K	-2.64M
Cash from Investing+	0	0	-214.37M	-74.93M	100.94M	-15.51M
Capital Expenditures	0	0	-262K	-275K	-514K	-241K
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	-74.66K	0	0
Cash from Financing+	2.95M	6.13M	323.55M	167.77M	53.33M	122.11M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	0	65K	2.37M	4.92M	466K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-2.64M	-6.2M	-38.91M	-99.05M	-167.04M	-131.11M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-1.34%	-5.28%	-1.55%	-0.69%	0.22%
FCF per Share	-1.35	-0.12	-0.77	-1.89	-2.85	-1.91
FCF Conversion (FCF/Net Income)	0.59x	0.22x	0.46x	0.91x	0.86x	0.97x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	1K	3K	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-67.39%	-34.25%	-64.56%	-54.27%
Return on Invested Capital (ROIC)	-	-	-52.97%	-34.01%	-62.97%	-50.33%
Debt / Equity	-	-	-	0.00x	0.05x	0.04x
Interest Coverage	-28.63x	-19.69x	-678.25x	-	-	-
FCF Conversion	0.59x	0.22x	0.46x	0.91x	0.86x	0.97x

Frequently Asked Questions

Growth & Financials

Ventyx Biosciences, Inc. (VTYX) grew revenue by 0.0% over the past year. Growth has been modest.

Ventyx Biosciences, Inc. (VTYX) reported a net loss of $106.6M for fiscal year 2024.

Dividend & Returns

Ventyx Biosciences, Inc. (VTYX) has a return on equity (ROE) of -54.3%. Negative ROE indicates the company is unprofitable.

Ventyx Biosciences, Inc. (VTYX) had negative free cash flow of $87.9M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener